Skip to main content
. 2021 Sep 30;36(5):938–951. doi: 10.3803/EnM.2021.501

Fig. 1.

Fig. 1

Relationship between the proportion of respondents willing to use thyroxine (T4)+triiodothyronine (T3) combination therapy in five European countries in patients with persistent symptoms despite a normal thyroid stimulating hormone on levothyroxine, and their annual per capita gross domestic product (GDP) in 2019 given as percentage of the world’s average. BG, Bulgaria [37]; RO, Romania [35]; PL, Poland [36]; IT, Italy [33]; DK, Denmark [34].